公开(公告)号：US12049464B2

公开(公告)日：2024-07-30

申请号：US17901775

申请日：2022-09-01

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20250018046A1

公开(公告)日：2025-01-16

申请号：US18576933

申请日：2022-07-07

Applicant: BIOGEN MA INC ,  C4 THERAPEUTICS, INC.

Inventor： Kevin M. Guckian ,  Emily Anne Peterson ,  Fang Gao ,  Ryan Evans ,  Eric Stefan ,  Jeremy L. Yap ,  Corey Don Anderson ,  Morgan Weizel O'Shea ,  Jae Young M. Ahn ,  Christopher G. Nasveschuk ,  James A. Henderson

IPC: A61K47/55 ,  A61K47/54

Abstract: This disclosure relates to compounds of Formula (A): Formula (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; Formula (I) in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.

公开(公告)号：US20210198256A1

公开(公告)日：2021-07-01

申请号：US17192634

申请日：2021-03-04

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap ,  Rhamy Zeid

IPC: C07D471/04 ,  C07D401/14 ,  C07D417/14

Abstract: Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.

公开(公告)号：US20230233692A1

公开(公告)日：2023-07-27

申请号：US18105735

申请日：2023-02-03

Applicant: C4 Therapeutics, Inc.

Inventor： James A. Henderson ,  Christopher G. Naveschuk ,  Kiel Lazarski ,  Victoria Garza ,  Moses Moustakim ,  Jae Young Ahn ,  Gesine Kerstin Veits ,  Morgan Welzel O'Shea ,  Ryan E. Michael ,  Jeremy L. Yap ,  Yanke Liang ,  Andrew Charles Good ,  Mark E. Fitzgerald ,  Robert T. Yu

IPC: A61K47/55

CPC classification number: A61K47/55

Abstract: Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.

公开(公告)号：US20230060334A1

公开(公告)日：2023-03-02

申请号：US17901775

申请日：2022-09-01

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US12157735B2

公开(公告)日：2024-12-03

申请号：US17965569

申请日：2022-10-13

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20240287076A1

公开(公告)日：2024-08-29

申请号：US18289438

申请日：2022-05-05

Applicant: BIOGEN MA INC. ,  C4 THERAPEUTICS, INC.

Inventor： Kevin M. Guckian ,  Eric Stefan ,  Corey Don Anderson ,  Jae Young Ahn ,  Morgan Welzel O'Shea ,  Jeremy L. Yap ,  Xinpeng Cheng ,  Brian T. Hopkins ,  Isaac Marx ,  Marta Nevalainen

IPC: C07D487/04 ,  A61K31/53

CPC classification number: C07D487/04 ,  A61K31/53

Abstract: This disclosure relates to compounds of Formula (A): BTK-L-DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches BTK to DSM, and BTK is a Btk binding moiety represented by Formula (I) or Formula (II) that is covalently attached to linker L: in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of Btk proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of Btk proteins. The present disclosure also provides methods of treating disorders responsive to modulation of Btk activity and/or degradation of Btk with at least one compound described herein.

公开(公告)号：US20230145336A1

公开(公告)日：2023-05-11

申请号：US18084380

申请日：2022-12-19

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Martin Duplessis ,  Mark E. Fitzgerald ,  Victoria Garza ,  Andrew Charles Good ,  Katrina L. Jackson ,  Yanke Liang ,  Moses Moustakim ,  Morgan Welzel O'Shea ,  Gesine Kerstin Veits ,  Jeremy L. Yap ,  Robert T. Yu ,  Cosimo Dolente ,  David Stephen Hewings ,  Daniel Hunziker ,  Bernd Kuhn ,  Piergiorgio Francesco Tommaso Pettazzoni ,  Fabienne Ricklin ,  Claus Riemer ,  Juergen Wichmann

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

公开(公告)号：US20240245677A1

公开(公告)日：2024-07-25

申请号：US18600097

申请日：2024-03-08

Applicant: C4 THERAPEUTICS, INC.

Inventor： Katrina L. Jackson ,  Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap ,  Minsheng He ,  Robert T. Yu ,  Matthew J. Schnaderbeck ,  Kathleen Neville ,  Siyi Jiang ,  Meiqi Li ,  Qianwei Liu ,  Manjie Zheng ,  Jia Li ,  Liwei Zhang

IPC: A61K31/496 ,  A61P35/00

CPC classification number: A61K31/496 ,  A61P35/00

Abstract: Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20240051953A1

公开(公告)日：2024-02-15

申请号：US17965569

申请日：2022-10-13

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  C07D401/14 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.